Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | ELANE | P08246 | 3/20 | 0.54 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | CTSG | P08311 | 1/20 | 0.46 |
| ▸ | CMA1 | P23946 | 1/20 | 0.46 |
| ▸ | CTRC | Q99895 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11608974 | 0.91 | MEN1 (0.62) | MGLLMEN1KMT2AELANEALDH1A1 | |
| SCHEMBL11607842 | 0.86 | MGLL (0.56) | MGLLMEN1KMT2AELANECTSG | |
| SCHEMBL11387780 | 0.85 | MEN1 (0.50) | MGLLMEN1KMT2AELANEPOLB | |
| SCHEMBL11610461 | 0.81 | MGLL (0.60) | MGLLMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL8504879 | 0.80 | MEN1 (0.65) | MGLLMEN1KMT2AELANEPOLB | |
| SCHEMBL8123624 | 0.79 | MEN1 (0.61) | MGLLMEN1KMT2AELANEF2 | |
| SCHEMBL11608666 | 0.78 | POLB (0.53) | MGLLMEN1KMT2AELANEPOLB | |
| SCHEMBL10834894 | 0.76 | MEN1 (0.61) | MGLLMEN1KMT2AELANEPOLB | |
| SCHEMBL7494006 | 0.76 | MGLL (0.56) | MGLLMEN1KMT2AELANEPOLB | |
| SCHEMBL11610740 | 0.75 | NPC1 (0.52) | MGLLMEN1KMT2AELANECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190134005-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARM INC (US) | 2019-05-09 | — | — | US | disclosed |
| WO-2017214505-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| EP-0044418-B1 | PROCESS FOR THE PREPARATION OF IMIDAZOLIDINE TRIONES | BAYER AG (DE) | 1984-02-22 | — | — | EP | disclosed |
| US-4384122-A | Process for the production of imidazolidine triones | BAYER AKTIENGESELLSCHAFT (DE) | 1983-05-17 | — | — | US | disclosed |
| EP-0044418-A1 | Process for the preparation of imidazolidine triones | BAYER AG (DE) | 1982-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190134005-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | UGCG, MAN2B1, GBA1 | MGLL 113/4885MEN1 1675/4885KMT2A 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.